Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA970A

Vaccine (Peptide vaccine) · Immune activation

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is IMA970A?

IMA970A is a multi-peptide therapeutic vaccine of sixteen peptides derived from tumor-associated antigens expressed by liver cancer cells, given intradermally. The liver-specific peptides are designed to activate CD4+ T-helper and CD8+ cytotoxic T-lymphocyte responses against hepatocellular carcinoma cells. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Mechanism
Immune activation
Therapy area
Oncology
In trials of
IMTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03203005 Phase 1/2 Hepatocellular Carcinoma Completed IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.